Montek (Sodium Molybdate (99mo))

Sodium Molybdate, the active ingredient in Montek, is a compound presented as a sterile aqueous solution for intravenous and ocular use. It is employed primarily in research and diagnostic contexts where molybdenum supplementation or imaging is required.

GNH USA supplies Montek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable cold‑chain logistics where required. Clients benefit from consistent batch-to-batch consistency and responsive technical support throughout the procurement process.

Sodium Molybdate is primarily used in research and diagnostic settings related to molybdenum metabolism.

Molybdenum deficiency research: provides a source of molybdenum to evaluate enzyme activity and metabolic pathways in vitro and in animal models. Ocular diagnostic imaging: employed as a contrast medium to enhance visualization of ocular structures during specialized imaging procedures. Analytical chemistry assays: used as a calibration standard for quantifying molybdenum concentrations in biological and environmental samples.

Sodium Molybdate may be associated with adverse reactions following intravenous or ocular administration.

Common Side Effects: - Injection site pain or erythema - Mild headache or transient visual disturbance - Nausea or low‑grade fever

Serious or Rare Side Effects: - Anaphylactic reaction or severe hypersensitivity - Acute renal impairment - Ocular toxicity leading to vision changes - Severe hypotension or thrombophlebitis

When using Montek, consider the following precautions.

Assess renal function: adjust use in patients with severe renal impairment. Monitor for hypersensitivity: discontinue if rash, swelling, or breathing difficulty occurs. Avoid in known molybdenum allergy: contraindicated in such individuals. Use caution in pregnancy: limited data, weigh potential benefits against risks. Observe ocular pressure: monitor intraocular pressure after ocular administration. Store at ambient temperature: keep in original container, protect from moisture and light.

Potential drug interactions with Sodium Molybdate should be reviewed before therapy.

Major Interactions (Avoid): - Copper supplements: may reduce molybdate absorption. - High‑dose zinc: can interfere with molybdenum metabolism. - Metal‑chelating antibiotics: may bind molybdate and diminish efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of coagulation parameters. - Diuretics: may affect renal excretion of molybdate.